vs
Enact Holdings, Inc.（ACT）与Penumbra Inc（PEN）财务数据对比。点击上方公司名可切换其他公司
Penumbra Inc的季度营收约是Enact Holdings, Inc.的1.2倍（$385.4M vs $312.7M），Penumbra Inc同比增速更快（22.1% vs 3.6%），过去两年Penumbra Inc的营收复合增速更高（17.6% vs 3.6%）
Enact Holdings, Inc.是美国领先的私人抵押贷款保险服务商，为银行、信用社等各类住宅抵押贷款机构提供风险缓释解决方案，帮助首付较低的购房者获得可负担的住房贷款，助力更多美国普通消费者实现安居需求。
Penumbra Inc是2004年由Arani Bose与Adam Elsesser联合创立的美国医疗器械企业，总部位于加利福尼亚州阿拉米达，核心业务为研发、生产中风、动脉瘤等血管疾病介入治疗所用的专业医疗设备，产品已在全球多个国家的临床诊疗场景中投入使用。
ACT vs PEN — 直观对比
营收规模更大
PEN
是对方的1.2倍
$312.7M
营收增速更快
PEN
高出18.5%
3.6%
两年增速更快
PEN
近两年复合增速
3.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $312.7M | $385.4M |
| 净利润 | — | $47.3M |
| 毛利率 | — | 68.0% |
| 营业利润率 | 71.3% | 15.4% |
| 净利率 | — | 12.3% |
| 营收同比 | 3.6% | 22.1% |
| 净利润同比 | — | 40.6% |
| 每股收益（稀释后） | $1.23 | $1.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACTPEN
| Q4 25 | $312.7M | $385.4M | ||
| Q3 25 | $311.5M | $354.7M | ||
| Q2 25 | $304.9M | $339.5M | ||
| Q1 25 | $306.8M | $324.1M | ||
| Q4 24 | $301.8M | $315.5M | ||
| Q3 24 | $309.6M | $301.0M | ||
| Q2 24 | $298.8M | $299.4M | ||
| Q1 24 | $291.6M | $278.7M |
净利润ACTPEN
| Q4 25 | — | $47.3M | ||
| Q3 25 | — | $45.9M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $39.2M | ||
| Q4 24 | — | $33.7M | ||
| Q3 24 | — | $29.5M | ||
| Q2 24 | — | $-60.2M | ||
| Q1 24 | — | $11.0M |
毛利率ACTPEN
| Q4 25 | — | 68.0% | ||
| Q3 25 | — | 67.8% | ||
| Q2 25 | — | 66.0% | ||
| Q1 25 | — | 66.6% | ||
| Q4 24 | — | 66.8% | ||
| Q3 24 | — | 66.5% | ||
| Q2 24 | — | 54.4% | ||
| Q1 24 | — | 65.0% |
营业利润率ACTPEN
| Q4 25 | 71.3% | 15.4% | ||
| Q3 25 | 67.4% | 13.8% | ||
| Q2 25 | 70.4% | 12.0% | ||
| Q1 25 | 68.9% | 12.4% | ||
| Q4 24 | 68.9% | 13.6% | ||
| Q3 24 | 74.1% | 11.7% | ||
| Q2 24 | 78.6% | -27.0% | ||
| Q1 24 | 70.6% | 4.3% |
净利率ACTPEN
| Q4 25 | — | 12.3% | ||
| Q3 25 | — | 12.9% | ||
| Q2 25 | — | 13.3% | ||
| Q1 25 | — | 12.1% | ||
| Q4 24 | — | 10.7% | ||
| Q3 24 | — | 9.8% | ||
| Q2 24 | — | -20.1% | ||
| Q1 24 | — | 3.9% |
每股收益（稀释后）ACTPEN
| Q4 25 | $1.23 | $1.20 | ||
| Q3 25 | $1.10 | $1.17 | ||
| Q2 25 | $1.11 | $1.15 | ||
| Q1 25 | $1.08 | $1.00 | ||
| Q4 24 | $1.05 | $0.88 | ||
| Q3 24 | $1.15 | $0.75 | ||
| Q2 24 | $1.16 | $-1.55 | ||
| Q1 24 | $1.01 | $0.28 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $582.5M | $186.9M |
| 总债务越低越好 | $744.5M | — |
| 股东权益账面价值 | $5.4B | $1.4B |
| 总资产 | $6.9B | $1.8B |
| 负债/权益比越低杠杆越低 | 0.14× | — |
8季度趋势，按日历期对齐
现金及短期投资ACTPEN
| Q4 25 | $582.5M | $186.9M | ||
| Q3 25 | $545.6M | $321.0M | ||
| Q2 25 | $616.0M | $421.8M | ||
| Q1 25 | $639.0M | $376.1M | ||
| Q4 24 | $602.8M | $324.4M | ||
| Q3 24 | $674.9M | $280.5M | ||
| Q2 24 | $711.3M | $288.3M | ||
| Q1 24 | $624.3M | $223.1M |
总债务ACTPEN
| Q4 25 | $744.5M | — | ||
| Q3 25 | $744.1M | — | ||
| Q2 25 | $743.8M | — | ||
| Q1 25 | $743.4M | — | ||
| Q4 24 | $743.0M | — | ||
| Q3 24 | $742.7M | — | ||
| Q2 24 | $742.4M | — | ||
| Q1 24 | $746.1M | — |
股东权益ACTPEN
| Q4 25 | $5.4B | $1.4B | ||
| Q3 25 | $5.3B | $1.4B | ||
| Q2 25 | $5.2B | $1.3B | ||
| Q1 25 | $5.1B | $1.2B | ||
| Q4 24 | $5.0B | $1.2B | ||
| Q3 24 | $5.0B | $1.1B | ||
| Q2 24 | $4.8B | $1.2B | ||
| Q1 24 | $4.7B | $1.2B |
总资产ACTPEN
| Q4 25 | $6.9B | $1.8B | ||
| Q3 25 | $6.9B | $1.7B | ||
| Q2 25 | $6.8B | $1.7B | ||
| Q1 25 | $6.7B | $1.6B | ||
| Q4 24 | $6.5B | $1.5B | ||
| Q3 24 | $6.6B | $1.5B | ||
| Q2 24 | $6.3B | $1.5B | ||
| Q1 24 | $6.3B | $1.6B |
负债/权益比ACTPEN
| Q4 25 | 0.14× | — | ||
| Q3 25 | 0.14× | — | ||
| Q2 25 | 0.14× | — | ||
| Q1 25 | 0.15× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.15× | — | ||
| Q2 24 | 0.15× | — | ||
| Q1 24 | 0.16× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $724.5M | $86.5M |
| 自由现金流经营现金流 - 资本支出 | — | $68.0M |
| 自由现金流率自由现金流/营收 | — | 17.7% |
| 资本支出强度资本支出/营收 | — | 4.8% |
| 现金转化率经营现金流/净利润 | — | 1.83× |
| 过去12个月自由现金流最近4个季度 | — | $174.9M |
8季度趋势，按日历期对齐
经营现金流ACTPEN
| Q4 25 | $724.5M | $86.5M | ||
| Q3 25 | $192.0M | $58.3M | ||
| Q2 25 | $119.5M | $44.9M | ||
| Q1 25 | $226.7M | $49.0M | ||
| Q4 24 | $686.3M | $51.1M | ||
| Q3 24 | $188.1M | $56.5M | ||
| Q2 24 | $144.7M | $22.6M | ||
| Q1 24 | $187.3M | $38.3M |
自由现金流ACTPEN
| Q4 25 | — | $68.0M | ||
| Q3 25 | — | $42.0M | ||
| Q2 25 | — | $29.4M | ||
| Q1 25 | — | $35.5M | ||
| Q4 24 | — | $45.7M | ||
| Q3 24 | — | $51.0M | ||
| Q2 24 | — | $18.1M | ||
| Q1 24 | — | $32.5M |
自由现金流率ACTPEN
| Q4 25 | — | 17.7% | ||
| Q3 25 | — | 11.8% | ||
| Q2 25 | — | 8.7% | ||
| Q1 25 | — | 11.0% | ||
| Q4 24 | — | 14.5% | ||
| Q3 24 | — | 16.9% | ||
| Q2 24 | — | 6.0% | ||
| Q1 24 | — | 11.7% |
资本支出强度ACTPEN
| Q4 25 | — | 4.8% | ||
| Q3 25 | — | 4.6% | ||
| Q2 25 | — | 4.6% | ||
| Q1 25 | — | 4.2% | ||
| Q4 24 | — | 1.7% | ||
| Q3 24 | — | 1.8% | ||
| Q2 24 | — | 1.5% | ||
| Q1 24 | — | 2.1% |
现金转化率ACTPEN
| Q4 25 | — | 1.83× | ||
| Q3 25 | — | 1.27× | ||
| Q2 25 | — | 0.99× | ||
| Q1 25 | — | 1.25× | ||
| Q4 24 | — | 1.52× | ||
| Q3 24 | — | 1.91× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 3.48× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACT
暂无分部数据
PEN
| Thrombectomy | $254.7M | 66% |
| Other | $130.7M | 34% |
